Shares of IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) have earned a consensus recommendation of “Hold” from the six brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $2.70.
A number of equities analysts recently issued reports on IPCI shares. Zacks Investment Research raised IntelliPharmaCeutics Intl from a “sell” rating to a “hold” rating in a report on Wednesday, December 13th. HC Wainwright started coverage on IntelliPharmaCeutics Intl in a report on Friday, January 19th. They set a “buy” rating and a $2.50 price target on the stock. Finally, Maxim Group set a $2.00 price target on IntelliPharmaCeutics Intl and gave the stock a “buy” rating in a report on Friday, February 9th.
A hedge fund recently bought a new stake in IntelliPharmaCeutics Intl stock. Armistice Capital LLC acquired a new stake in IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,936,000 shares of the company’s stock, valued at approximately $1,549,000. Armistice Capital LLC owned approximately 6.23% of IntelliPharmaCeutics Intl at the end of the most recent quarter. Hedge funds and other institutional investors own 11.31% of the company’s stock.
IntelliPharmaCeutics Intl (IPCI) traded down $0.04 on Friday, hitting $0.58. The stock had a trading volume of 127,618 shares, compared to its average volume of 397,437. IntelliPharmaCeutics Intl has a twelve month low of $0.57 and a twelve month high of $2.92. The firm has a market capitalization of $21.86, a PE ratio of -2.01 and a beta of 1.23.
IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) last posted its earnings results on Friday, February 16th. The company reported ($0.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.01). IntelliPharmaCeutics Intl had a negative return on equity of 2,811.75% and a negative net margin of 160.89%. The firm had revenue of $1.08 million for the quarter, compared to analyst estimates of $1.32 million. equities research analysts predict that IntelliPharmaCeutics Intl will post -0.18 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/03/13/intellipharmaceutics-intl-inc-ipci-receives-2-70-consensus-pt-from-analysts.html.
About IntelliPharmaCeutics Intl
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.